Erectile function in men
Wessells 2000 (n=20) randomized men with erectile dysfunction to MT-II or placebo in crossover design and showed penile erection in 17/20 men in the absence of stimulation, with 68% reporting increased sexual desire vs 19% on placebo. Subsequent work led to development of bremelanotide (PT-141), a closely related analog, while MT-II itself was abandoned for clinical use due to off-target tanning, nausea, and melanocytic effects.
2 human studies · 8 animal studies
Key findings & citations
- Wessells 2000: erection in 17/20 men with ED on MT-II vs minimal on placebo.
- Sexual desire increased 68% vs 19% placebo.
- Severe nausea in ~13% at 0.025 mg/kg — meaningful tolerability cost.
- Bremelanotide (PT-141) replaced MT-II in clinical development.
Our take
Real pro-erectile effect, dirty side-effect profile. PT-141 is the cleaner version of the same idea.